Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 653-660

  Wehmeier, Peter M ^a,b   Schacht, Alexander ^c   Ulberstad, Fredrik ^d   Lehmann, Martin ^c   Schneider Fresenius, Christian ^c   Lehmkuhl, Gerd ^e   Dittmann, Ralf W ^a   Banaschewski, Tobias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Vitos Hospital for Psychiatry and Psychotherapy   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d KARLSTAD UNIVERSITY   (Sweden)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

ADHD; atomoxetine; continuous performance test; executive function; quantitative measurement

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT; PLACEBO;

AGGRESSION; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BODY WEIGHT; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONDUCT DISORDER; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DSM-IV; EXECUTIVE FUNCTION; FATIGUE; FEMALE; GASTROENTERITIS; HEART RATE; HUMAN; IMPULSIVENESS; INFLUENZA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; NAUSEA; OPPOSITIONAL DEFIANT DISORDER; PERFORMANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REACTION TIME; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SORE THROAT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DIAGNOSIS, COMPUTER-ASSISTED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865865084     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318267c304     Document Type: Article

References (42)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237-248.
2. di Michele F, Princhep L, John ER, et al. The neurophysiology of attention-deficit/hyperactivity disorder. Int J Psychophysiol. 2005;58:81-93.
3. Levy F, Hobbes G. The action of stimulant medication in attention deficit disorder with hyperactivity: dopaminergic, noradrenergic, or both? J Am Acad Child Adolesc Psychiatry. 1988;27(6):802-805.
4. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs. 2009;23(suppl 1):33-41.
5. Doyle AE. Executive functions in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(suppl 8):21-26.
6. Riccio CA, Reynolds CR, Lowe P, et al. The continuous performance test: a window on the neural substrates for attention? Arch Clin Neuropsychol. 2002;17:235-272.
7. Epstein JN, Conners CK, Hervey AS, et al. Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry. 2006;47:446-456.
8. Levy F, Hobbes G. Discrimination of attention deficit hyperactivity disorder by the continuous performance test. J Paediatr Child Health. 1997;33(5):384-387.
9. Maziade M, Rouleau N, Lee B, et al. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19:709-718.
10. Porrino LJ, Rapoport JL, Behar D, et al. A naturalistic assessment of the motor activity of hyperactive boys. I. Comparison with normal controls. Arch Gen Psychiatry. 1983;40:681-687.
11. Taylor E. Clinical foundations of hyperactivity research. Behav Brain Res. 1998;94:11-24.
12. Döpfner M, Lehmkuhl G. DISYPS-JK: Diagnostik-System für psychiche Störungen im Kindes-und Jugendalter nach ICD-10 und DSM-IV. Bern, Switzerland: Verlag Hans Huber; 2000.
13. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, NY: The Guilford Press; 1998:28-42.
14. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:107-115.
15. Schechter MD, Timmons GD. Objectively measured hyperactivityVI. Comparison with normal controls. J Clin Pharmacol. 1985;25:269-275.
16. Halperin JM, Matier KM, Bedi G, et al. Specificity of inattention, impulsivity and hyperactivity to the diagnosis of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1992;31:190-196.
17. Teicher MH, Ito Y, Glod CA, et al. Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatr. 1996;35:334-342.
18. Teicher MH, Anderson CM, Polcari A, et al. Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat Med. 2000;6:470-473.
19. Teicher MH, Polcari A, McGreenery CE. Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18:265-270.
20. Heiser P, Frey J, Smidt J, et al. Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate. Eur Child Adolesc Psychiatry. 2004;13:100-104.
21. Tabori-Kraft J, Sørensen MJ, Kaergaard M, et al. Is OPTAx useful for monitoring the effect of stimulants on hyperactivity and inattention? A brief report. Eur Child Adolesc Psychiatry. 2007;16:347-351.
22. Brocki KC, Tillman CM, Bohlin G. CPT performance, motor activity, and continuous relations to ADHD symptom domains: a developmental study. Eur J Dev Psychol. 2010;7(2):178-197.
23. Oades RD, Myint AM, Dauvermann MR, et al. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav Brain Funct. 2010;6:32.
24. Paulus MP, Geyer MA. A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology. 1991;104:6-16.
25. Tannock R. Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry. 1998;39:65-99.
26. Denckla MB. Research on executive function in a neurodevelopmental context: application of clinical measures. Dev Neuropsychol. 1996;12:5-15.
27. Castellanos FX, Sonuga-Barke EJ, Scheres A, et al. Varieties of attention-deficit/hyperactivity disorder-related intra-individual variability. Biol Psychiatry. 2005;57:1416-1423.
28. Salthouse TA. Attentional blocks are not responsible for age-related slowing. J Gerontol. 1993;48:263-270.
29. Barkley RA. The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. J Abnorm Child Psychol. 1991;19:149-178.
30. Halperin JM, Wolf L, Greenblatt ER, et al. Subtype analysis of commission errors on the Continuous Performance Test. Dev Neuropsychol. 1991;7:207-217.
31. Rubia K, Overmeyer S, Taylor E, et al. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. 1999;156:891-896.
32. Knagenhjelm P, Ulberstad F. Quantified Behavioral Test (QbTest) Technical Manual. Stockholm, Sweden: Qbtech; 2010.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare; 1976;338:534-537.
34. National Institutes of Mental Health (NIMH). Clinical global impressions. Psychopharmacol Bull. 1985;21:839-943.
35. Wehmeier PM, Dittmann RW, Schacht A, et al. Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health. 2009;3:5.
36. Friendly M. Corrgrams: exploratory displays for correlation matrices. Am Stat. 2002;56:316-324.
37. Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescentsVmeta- analysis and meta-regression analysis. Psychopharmacology. 2007;194:197-209.
38. Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naBve Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18:240-249.
39. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T. 2009;34:678-694.
40. Newcorn JH, Sutton VK, Zhang S, et al. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1165-1172.
41. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
42. Wehmeier PM, Schacht A,Wolff C, et al. Neuropsychological outcomes across the day in children with ADHD treated with atomoxetine. Results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion tracking device. J Child Adolesc Psychopharmacology. 2011;21:433-444.